HISTONE DEACETYLASE INHIBITOR INDUCED ANTI-MYELOMA ACTIVITY IS MEDIATED PRINCIPALLY VIA CLASS I DEACETYLASE INHIBITION

被引：0
|
作者：
Mithraprabhu, S. [1 ]
Kalff, A. [2 ]
Quach, H. [3 ]
Khong, T. [4 ]
Andrew, A. [5 ,6 ]
机构：
[1] Monash Univ, Alfred Hlth, Melbourne, Vic, Australia
[2] Alfred Hosp, Malignant Hematol & Stem Cell Transplantat, Melbourne, Vic, Australia
[3] Monash Univ, Dept Clin Hematol, Clayton, Vic, Australia
[4] Monash Univ, Alfred Hosp, Australian Ctr Blood Dis, Melbourne, Vic, Australia
[5] Monash Univ, Alfred Hosp, ACBD, MH&SCT, Melbourne, Vic, Australia
[6] Monash Univ, Alfred Hosp, DCH, Melbourne, Vic, Australia
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0260
引用
收藏
页码：104 / 105
页数：2
相关论文
共 50 条
  • [1] In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor
    Neri, Paola
    Tagliaferri, Pierosandro
    Di Martino, Maria Teresa
    Calimeri, Teresa
    Amodio, Nicola
    Bulotta, Alessandra
    Ventura, Monica
    Eramo, Pasqua Orietta
    Viscomi, Caterina
    Arbitrio, Mariamena
    Rossi, Marco
    Caraglia, Michele
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    Tassone, Pierfrancesco
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 143 (04) : 520 - 531
  • [2] The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
    Sanchez, Eric
    Shen, Jing
    Steinberg, Jeffrey
    Li, Mingjie
    Wang, Cathy
    Bonavida, Benjamin
    Chen, Haiming
    Li, Zhi-Wei
    Berenson, James R.
    LEUKEMIA RESEARCH, 2011, 35 (03) : 373 - 379
  • [3] Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC
    Mithraprabhu, Sridurga
    Khong, Tiffany
    Jones, Simon S.
    Spencer, Andrew
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (04) : 559 - 562
  • [4] Molecular profile of the anti-myeloma activity of histone deacetylase (HDAC) inhibitors: Biological and therapeutic implications.
    Mitsiades, CS
    Mitsiades, N
    McMullan, CJ
    Poulaki, V
    Shringarpure, R
    Hideshima, T
    Akiyama, M
    Chauhan, D
    Munshi, NC
    Joseph, M
    Libermann, TA
    Richon, VM
    Marks, PA
    Anderson, KC
    BLOOD, 2003, 102 (11) : 189A - 189A
  • [5] Class I Histone Deacetylase Inhibitor Therapy in the Treatment of Hepatoblastoma
    Whitlock, R.
    Srivastava, R.
    Patel, R.
    Larson, S.
    Woodfield, S.
    Vasudevan, S.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S273 - S273
  • [6] Anti-parasitic activity of depudecin on Neospora caninum via the inhibition of histone deacetylase
    Kwon, HJ
    Kim, JH
    Kim, M
    Lee, JK
    Hwang, WS
    Kim, DY
    VETERINARY PARASITOLOGY, 2003, 112 (04) : 269 - 276
  • [7] Use of class I histone deacetylase inhibitor romidepsin in combination regimens
    Petrich, Adam
    Nabhan, Chadi
    LEUKEMIA & LYMPHOMA, 2016, 57 (08) : 1755 - 1765
  • [8] Class I Histone Deacetylase Inhibition for the Treatment of Sustained Atrial Fibrillation
    Seki, Mitsuru
    LaCanna, Ryan
    Powers, Jeffery C.
    Vrakas, Christine
    Liu, Fang
    Berretta, Remus
    Chacko, Geena
    Holten, John
    Jadiya, Pooja
    Wang, Tao
    Arkles, Jeffery S.
    Copper, Joshua M.
    Houser, Steven R.
    Huang, Jianhe
    Patel, Vickas V.
    Recchia, Fabio A.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2016, 358 (03): : 441 - 449
  • [9] Histone Deacetylase Inhibitors: A Review on Class-I Specific Inhibition
    Behera, Jagannath
    Jayprakash, Venkatesan
    Sinha, Barij Nayan
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2015, 15 (09) : 731 - 750
  • [10] Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001
    Ramakrishnan, Vijay
    Kimlinger, Teresa
    Timm, Michael
    Haug, Jessica
    Rajkumar, Vincent
    Kumar, Shaji
    LEUKEMIA RESEARCH, 2014, 38 (11) : 1358 - 1366
12345